FLEETCOR Technologies, Inc. (FLT)

Revenue of $10,587,075 in Q2 2025, up 49% year-over-year; gross margin of 32% Adjusted EBITDA loss of $276,259, an 85% year-over-year improvement Current cash balance strengthened to approximately $20M Operational highlights included clearances and demonstrations with defense and energy clients and new commercial wins in forestry and agriculture. Subsequent events included additional NATO-aligned contracts and growth capital TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three and six months ended June 30, 2025 (Q2 2025).

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has completed its previously announced bought deal private placement offering of securities, including the exercise in full of the Underwriter's (as defined below) over-allotment option, of a total of 9,288,462 units of the Company (the “Offered Securities”) at a price of $0.52 per Offered Security for gross proceeds of $4,830,000 (the “Offering”). The Offering was led by institutional investors in Quebec, with strong participation from additional institutional investors across Canada, underscoring the broad confidence in Volatus' strategy and growth potential.The Offering was led by Ventum Financial Corp. as underwriter and sole bookrunner (the “Underwriter”).

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce it has entered into an agreement with Ventum Financial Corp. (the "Underwriter") in connection with a bought deal private placement of 8,076,924 units of the Company (the “Offered Securities”) at a price of $0.52 per Offered Security (the “Issue Price”) for gross proceeds of $4,200,000 (the “Offering”).   Each Offered Security will consist of one common share of the Company and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to acquire one common share of the Company at an exercise price of $0.76 and for a period of 36 months following the Closing Date (as defined below).

TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB), a Canadian leader in aerial intelligence and cargo solutions, is pleased to announce the launch of its Condor XL heavy-lift drone program. Drawing on decades of helicopter operations experience, in-house avionics capabilities, and a renewed focus on rotorcraft-specific training, the company is introducing a next-generation platform designed to meet global demand for autonomous, heavy-lift drone solutions.

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Corp. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) ("Volatus" or the "Company") is pleased to announce that it has been awarded a contract valued at approximately $560,000 CAD to provide advanced training in drone operations and sensor payload utilization to support aerial intelligence. The contract reinforces the Company's role as a trusted provider of mission-critical capabilities for government programs.

TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) welcomes the Government of Canada's pledge to increase defense spending to 2% of GDP and its endorsement of NATO's new target of defense spending to 5% by 2035. These measures signal Canada's strengthened commitment to national sovereignty and collective allied readiness and represent a transformative moment for the Canadian defense and aerospace industry.

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce the successful closing of a $3 million private placement (the “Financing”) from Investissement Québec. Pursuant to the Financing, the Company entered into an amended and restated secured convertible debenture (the “Debenture”) increasing the principal amount of Investissement Québec's original investment of $7.5 million, as announced in the Company's news release dated October 21, 2024, to an aggregate of $10.5 million.

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Generated revenue of $5,713,158 in Q1 2025 Achieved 30% EBITDA improvement over Q1 2024 Continuation of optimization efforts post Volatus and Drone Delivery Canada merger of equals Subsequent to quarter end, closed $3,000,000 fully subscribed LIFE Offering Subsequent to quarter end, announced closing of shares for debt transaction of $2,646,000 and an additional $446,400, strengthening balance sheet Volatus will host a webinar and live Q&A on Monday, June 2, 2025, at 8 am ET (see registration link below). TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three months ended March 31, 2025 (Q1 2025).

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. The Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with holders of unsecured non-convertible debentures of Volatus Aerospace Corp., a wholly-owned subsidiary of the Company (the “Debentures”), to settle the outstanding principal and accrued and unpaid interest owing under the Debentures as at the maturity date, being May 23, 2025, in the aggregate amount of $446,400 in consideration for the issuance of an aggregate of 3,720,000 units of the Company (the “Settlement Units”) at a deemed price of $0.12 per Settlement Unit (the “Shares-for-Debt Transaction”).

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce that, further to its press release dated April 11, 2025, the Company has completed its previously announced shares-for-debt transaction (the “Shares-for-Debt Transaction”) and issued a total of 20,174,280 common voting shares in the capital of the Company (the “Common Shares”) and 17,640,000 Common Share purchase warrants (each a “Warrant”) settling an aggregate debt of $3,026,142.00 owing to holders of unsecured convertible debentures of the Company (the “Debentures”) issued pursuant to a debenture indenture dated May 11, 2023 between the Company and TSX Trust Company. To give effect to the Shares-for-Debt Transaction, the Company and TSX Trust Company, as trustee, entered into a third supplemental indenture to the debenture indenture governing the Debentures.

Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.

Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).